Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EG5A
|
|||
| Former ID |
DNCL002641
|
|||
| Drug Name |
Retaspimycin
|
|||
| Synonyms |
UNII-BZF2ZM0I5Z; IPI-504; BZF2ZM0I5Z; CHEBI:71975; 857402-23-4; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(allylamino)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[1631]docosa-1(22),4,6,10,18,20-hexaen-9-yl carbamate; Retaspimycin [USAN:INN]; Retaspimycin (USAN/INN); SCHEMBL13199500; CHEMBL1184904; SCHEMBL12251507; ZINC43128334; AN-27116; D09375; Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-; 17 AAGH2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Discontinued in Phase 2 | [1] | |
| Company |
Infinity Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H45N3O8
|
|||
| Canonical SMILES |
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)C)OC)OC(=O)N)C)C)O)OC
|
|||
| InChI |
1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
|
|||
| InChIKey |
OAKGNIRUXAZDQF-TXHRRWQRSA-N
|
|||
| CAS Number |
CAS 857402-23-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:71975
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021934) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.